Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DLX vs HHS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DLX Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 6–4 Matrix Metrics)

DLX Overall Winner 6-Pillar Tally: DLX 5 – 0 HHS (1 Tie) Matrix Metrics: DLX 6 – 4 HHS

As of Nov 16, 2026, Deluxe Corporation (DLX) is the stronger overall head-to-head candidate over Harte Hanks, Inc. (HHS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DLX carries a Unified Composite Score of 31.4/100 (SELL) at $27.15 (6.5x Forward P/E, 12.8% operating margin), whereas HHS carries 61.8/100 (BUY) at $3.85 (14.3x Forward P/E, -3.2% operating margin).

  • Composite vs. Pillar Nuance: While HHS currently prints a higher short-term Unified Composite Score (61.8/100 BUY vs. DLX 31.4/100 SELL), DLX captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (12.8% vs. -3.2% operating margin) and revenue trajectory (+2.5% vs. -1.7% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DLX vs HHS
DLX NYSE Head-to-Head Winner
Deluxe Corporation
Blankbooks, Looseleaf Binders & Bookbindg & Relatd Work
$27.15
+1.38% 1D
Market Cap $1.2B
TTM Revenue $2.13B
Forward P/E 6.5x
Beta / 30D Vol -0.45β · 75% Vol
Unified Composite Score
31.4 / 100 SELL
Tech 50.0 Fund 28.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.2% over 20 days), RSI 66
RSI-14: 65.8 · SMA20: $24.52 · SMA50: $23.80
HHS US Equity
Harte Hanks, Inc.
Services-Direct Mail Advertising Services
$3.85
-3.99% 1D
Market Cap $30.0M
TTM Revenue $155M
Forward P/E 14.3x
Beta / 30D Vol 0.49β · 46% Vol
Unified Composite Score
61.8 / 100 BUY
Tech 76.0 Fund 61.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 38
RSI-14: 38.2 · SMA20: $3.95 · SMA50: $4.26

6-Pillar Scorecard Institutional Category Breakdown (DLX 5 – 0 HHS)

Columns: Metric · DLX · HHS
1. Valuation Multiples DLX
Forward P/E 6.5x 14.3x
Trailing P/E 15.5x 14.3x
PEG Ratio 0.53x 1.19x
EV / Revenue 0.6x 0.3x
2. Growth & Scale DLX
Revenue Growth (YoY) +2.5% -1.7%
Earnings Growth (YoY) -62.2% -90.3%
TTM Revenue (USD) $2.13B $155M
Market Cap $1.2B $30.0M
3. Profitability & Quality DLX
Gross Margin 52.1% 16.1%
Operating Margin 12.8% -3.2%
Net Profit Margin 3.8% -3.7%
Return on Equity (ROE) 11.6% -30.4%
4. Balance Sheet & Cash Flow DLX
Cash Generation (TTM) $428M EBITDA -$4.5M
Cash Flow Margin 20.1% EBITDA Mgn -2.9%
Net Cash / Leverage $15.63 Book/Sh · 11.6% ROE $17M Net Debt (1.10x D/E)
Dividend Yield 4.52% None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 24.9% (<1st %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat DLX
OpEx & R&D Intensity 39.3% of Rev ($836M) 19.3% of Rev ($30M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Conglomerates Operator Conglomerates Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DLX (6) vs HHS (4)
Institutional Metric DLX HHS Criterion Row Edge
Market Capitalization
Scale
$1.2B $30.0M Larger Scale DLX
Trailing P/E Ratio
Valuation
15.5x 14.3x Lower Multiple HHS
Forward P/E Ratio
Valuation
6.5x 14.3x Lower Multiple DLX
Revenue Growth (YoY)
Growth
+2.5% -1.7% Higher Growth DLX
Operating Margin (TTM)
Profitability
12.8% -3.2% Higher Margin DLX
Net Profit Margin
Profitability
3.8% -3.7% Higher Margin DLX
Return on Equity (ROE)
Capital Efficiency
11.6% -30.4% Higher ROE DLX
52-Week Range Position
Momentum
64% ($19–$32) 69% ($2–$5) Stronger Trend HHS
Beta / 30D Volatility
Risk Regime
-0.45β · 75% Vol 0.49β · 46% Vol Lower Realized Risk HHS
Unified Institutional Score
Composite Signal
31.4 / 100 (SELL) 61.8 / 100 (BUY) Higher Composite HHS
Trailing 12M Revenue (USD)
Operating Scale
$2.13B $155M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
52.1% 16.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.53x PEG · 0.6x EV/Rev 1.19x PEG · 0.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$428M EBITDA ($15.63 Book/Sh · 11.6% ROE) -$4.5M ($17M Net Debt (1.10x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DLX +27.39 pp
DLX: +17.13% · HHS: -10.26%
3M Horizon DLX +19.93 pp
DLX: +16.42% · HHS: -3.51%
6M Horizon HHS +34.38 pp
DLX: +2.14% · HHS: +36.52%
1Y Horizon HHS +2.26 pp
DLX: +32.83% · HHS: +35.09%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DLX vs HHS. Trailing 12-month operating profitability (DLX 12.8% vs HHS -3.2%) and valuation multiples (DLX 6.5x vs HHS 14.3x Forward P/E) are benchmarked directly in Pillar 4 below.

DLX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.13B
Gross Margin52.1%
Op. Margin12.8%
ROE / Fwd P/E11.6% · 6.5x
HHS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$155M
Gross Margin16.1%
Op. Margin-3.2%
ROE / Fwd P/E-30.4% · 14.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DLX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 24.9%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DLX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
HHS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact HHS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DLX Moat Profile Cyclical / Execution-Driven Positioning
Conglomerates Operator
Competes within the Conglomerates value chain with $1.2B market capitalization and 12.8% operating margin.
OpEx & R&D Reinvestment 39.3% of Rev ($836M)
90D Engineering Disclosures 0 Published
HHS Moat Profile Cyclical / Execution-Driven Positioning
Conglomerates Operator
Competes within the Conglomerates value chain with $30.0M market capitalization and -3.2% operating margin.
OpEx & R&D Reinvestment 19.3% of Rev ($30M)
90D Engineering Disclosures 0 Published

Investor FAQ DLX vs HHS Key Questions & Quantitative Answers

As of Nov 16, 2026, Deluxe Corporation (DLX) is the stronger overall head-to-head candidate over Harte Hanks, Inc. (HHS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DLX carries a Unified Composite Score of 31.4/100 (SELL) at $27.15 (6.5x Forward P/E, 12.8% operating margin), whereas HHS carries 61.8/100 (BUY) at $3.85 (14.3x Forward P/E, -3.2% operating margin). Composite vs. Pillar Nuance: While HHS currently prints a higher short-term Unified Composite Score (61.8/100 BUY vs. DLX 31.4/100 SELL), DLX captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (12.8% vs. -3.2% operating margin) and revenue trajectory (+2.5% vs. -1.7% YoY).

DLX leads the Growth & Scale pillar: DLX posts +2.5% YoY revenue growth and -62.2% YoY earnings growth on $2.13B TTM revenue (52.1% gross margin, 12.8% operating margin), compared with HHS at -1.7% YoY revenue growth and -90.3% YoY earnings growth on $155M TTM revenue (16.1% gross margin, -3.2% operating margin). On trailing 12-month operating scale, DLX generates $2.13B in USD-normalized revenue versus $155M for HHS. In operating R&D and SG&A reinvestment, DLX deploys 39.3% of Rev ($836M) (0 90-day corporate R&D disclosures) versus 19.3% of Rev ($30M) (0 disclosures) for HHS.

DLX screens cheaper on headline valuation multiples. DLX trades at 6.5x Forward P/E, 15.5x Trailing P/E, 0.53x PEG, and 0.6x EV/Revenue (20.1% EBITDA margin), whereas HHS trades at 14.3x Forward P/E, 14.3x Trailing P/E, 1.19x PEG, and 0.3x EV/Revenue (-2.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DLX (11.6% ROE) versus HHS (-30.4% ROE) capital efficiency.

In options market volatility and institutional positioning, DLX carries 24.9% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.45β · 75% Vol realized risk). By comparison, HHS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.49β · 46% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.